Elcin Barker Ergun, Menarini Group CEO

Amid Roche and Sanofi's oral SERD set­backs, Menar­i­ni gets speedy re­view at FDA

Menar­i­ni and Ra­dius Health are get­ting a speedy re­view at the FDA for their oral SERD breast can­cer drug months af­ter the field opened up with com­peti­tors fail­ing and flee­ing.

It was a one-two-three punch in March, April and May as Sanofi flunked its first big test for its oral se­lec­tive es­tro­gen re­cep­tor de­grad­er (SERD), Roche al­so flamed out in a Phase II and G1 Ther­a­peu­tics end­ed its pro­gram af­ter scop­ing out the da­ta and po­ten­tial part­ners.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.